Skip to content

ACS Med Chem Lett

ISSN 1948-5875

22 papers in the library · 6 citations · publishing 2023-2026

Papers

Sort Most recent Most cited

Chemical Design and Pharmacokinetics Enable Precision Psychedelic Therapeutics.

ACS Med Chem Lett January 12, 2026

Recent psychedelic patent activity highlights a strategic shift from experiential framing toward chemically and pharmacokinetically precise neurotherapeutics. Four recent patent applications collectively span solid-state control of psilocybin, exposure-shaped intramuscular and infusion-based dosing, and chemically diversified monoaminergic scaffolds with defined transporter and receptor...

DOI: 10.1021/acsmedchemlett.5c00780 (opens in new tab)

From Solid-State Control to Predictive Precision: Building a Deployable Ecosystem for Psychedelic Therapeutics.

ACS Med Chem Lett January 12, 2026

Two recent patent applications illustrate how psychedelic drug development is expanding beyond molecules and experiences toward deployable therapeutic systems. One focuses on solid-state optimization of a lysergamide analogue to ensure manufacturability and stability, while the other applies machine-learning-driven neurophysiological biomarkers to predict patient response. Together, they...

DOI: 10.1021/acsmedchemlett.5c00782 (opens in new tab)

Engineering the Next Generation of Psychedelic Therapeutics through Serotonergic Precision and Pharmacokinetic Control.

ACS Med Chem Lett November 10, 2025

High Resolution Image Download MS PowerPoint Slide Recent patents unveil a new wave of psychedelic analogs optimized for 5-HT 2 A receptor modulation, reduced adverse effects, and tunable duration of action. By refining DMT and psilocin scaffolds through prodrug design, fluorination, and structure–activity exploration, these innovations promise safer, shorter-acting psychedelic medicines that...

DOI: 10.1021/acsmedchemlett.5c00661 (opens in new tab)

Toward Precision Psychedelic Therapies: Chemical, Computational, and Neuromodulatory Innovations.

ACS Med Chem Lett October 9, 2025

Recent patents disclose complementary strategies to optimize psychedelic-assisted therapy. Novel psilocin prodrugs improve pharmacokinetics and stability, while digital systems enable cognitive state monitoring during treatment. Parallel advances in combining neuroplastogen drugs with transcranial electrical stimulation highlight a model-driven approach to enhance and personalize neural...

DOI: 10.1021/acsmedchemlett.5c00597 (opens in new tab)

Novel Indoline Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis, Mental Illness and CNS Disorders.

ACS Med Chem Lett January 23, 2025 Ram W. Sabnis, Anika R. Sabnis 3 citations

Provided herein are novel indoline derivatives as serotonergic psychedelic agents, pharmaceutical compositions, use of such compounds in treating psychosis, mental illness and central nervous system (CNS) disorders and processes for preparing such compounds.

DOI: 10.1021/acsmedchemlett.5c00004 (opens in new tab) Full text (opens in new tab)

Advances in Psychedelic Therapeutics: Novel Prodrugs and Derivatives for Enhanced Mental Health Treatment.

ACS Med Chem Lett November 11, 2024 Robert B. Kargbo

High Resolution Image Download MS PowerPoint Slide Recent innovations in psychedelic research have led to the development of novel compounds designed to enhance the therapeutic potential of psilocin and related tryptamines. This Patent Highlight reviews three essential patents that focus on improving the stability, bioavailability, and efficacy of these compounds for treating mental health...

DOI: 10.1021/acsmedchemlett.4c00519 (opens in new tab)

Pioneering Changes in Psychiatry: Biomarkers, Psychedelics, and AI.

ACS Med Chem Lett August 18, 2023 Robert B. Kargbo 3 citations

This viewpoint discusses integrating biomarkers, psychedelics, and AI into psychiatry for enhanced diagnostics, prognosis, and treatment. It highlights the potential of psychedelics in therapy, AI's role in predicting treatment response, and the challenges that must be addressed. The aim is to encourage research for more precise, personalized psychiatric care.

DOI: 10.1021/acsmedchemlett.3c00333 (opens in new tab) Full text (opens in new tab) Psychedelic therapy Mental health Personalized medicine Medical innovation +1